← Back to Calendar

Travere Therapeutics Q4 2025 Earnings

Travere Therapeutics · $TVTX
Standard Review Earnings
Catalyst Date
February 27, 2026
Date Status
45d ago (past)
Review Type
Standard (10 mo)

Live Company Data NGM

Updated 25m ago · Data: FMP
Current Price
$28.96 +114.68%
+$15.47 today
Day: $28.29 – $31.47
Market Cap
N/A
Shares out: 92.37M
Float: 91.22M
52-Week Range
$13.88
$42.13
Current price is at 53% of 52-week range
Avg Volume
1.55M
Beta
0.87
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $TVTX catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

Q4 2025 earnings + FILSPARI commercial + FSGS PDUFA update

Key Notes

Q4 2025 earnings reported ~February 27, 2026. Record Q4 FILSPARI demand: 908 new patient starts in IgAN. FY2025 revenue $490.73M (+110% YoY). FSGS sNDA PDUFA extended to April 13, 2026 after major amendment in January 2026.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar